SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA

SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ — SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of…